Status: Recruiting
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in (Stratum 1) adult patients with newly diagnosed GBM (MGMT low level or unmethylated in adults only) and (Stratum 2) in pediatric patients with newly diagnosed HGG (pHGG). Funding Source - FDA OOPD
Participants needed: 28
Trial details
Phase: Phase 1Age: 4+Biological sex: AllType: InterventionalSponsor: University of FloridaUpdated: Jun 25, 2026Locations: 2
Eligibility criteria
Age ≥ 21 years. [+44]
Prior invasive malignancy (except for non-melanomatous skin cancer) unless disea... [+39]